title: [Construction and application of a genechip method for detection of hepatitis B virus lamivudine-resistant mutants and basal core promotor/Pre-C mutants].
abstract: OBJECTIVE
  The objective of this research is to construct a clinic-usable genechip method for detection of hepatitis B virus lamivudine-resistant mutants and basal core promotor/Pre-C mutants, compare this method with DNA sequencing to investigate this genechip's character (sensity, specificity, stability and practicability in clinic) and apply it in clinic.
  
  
  METHODS
  This genechip detection method can detect the DNA and 8 mutative site of HBV, include 3 lamivudine-resistant mutation site(No. 180, 204, 207 site in DNA polymerase gene), 5 HBeAg escape-related mutation site (nt 1896, 1899, 1862, 1764,1762 site in BCP/Pre-C region).The results of genechip method was verified by DNA sequencing.
  
  
  RESULTS
  In detecting HBV DNA, the results of genechip were agree with 100% of the results of DNA sequencing. In detecting HBV mutants, 251 sites (in 32 samples, 256 sites) showed the same results using both methods, and only 5 sites were not completely match (P > 0.05). In these 5 sites, genechip methods got multi-infection results, but sequencing got single-infection results.
  
  
  CONCLUSIONS
  These results suggest that genechip method has the same positive rate and almost these same specificity with DNA sequencing method, and is better than DNA sequencing method in detecting multi-infected HBV strains. [Key words]
authors.affiliation: Infection Department, Shenzhen Disanrenmin Hospital of Guangdong Medical College, Shenzhen 518020, China
authors.forename: Bing
authors.initials: B
authors.lastname: Li
authors.forename: Bo-Ping
authors.initials: BP
authors.lastname: Zhou
authors.forename: Jin-Fu
authors.initials: JF
authors.lastname: Peng
authors.forename: Li-Yan
authors.initials: LY
authors.lastname: Chen
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Tang
authors.forename: Zhao-Qin
authors.initials: ZQ
authors.lastname: Wang
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Yin
authors.forename: Liu-Mei
authors.initials: LM
authors.lastname: Xu
authors.forename: Rui-Ling
authors.initials: RL
authors.lastname: Luo
authors.forename: Xiao-He
authors.initials: XH
authors.lastname: Li
authors.forename: Sai-Yun
authors.initials: SY
authors.lastname: Liu
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D024882:Drug Resistance, Viral; D006509:Hepatitis B / Q000188:drug therapy / Q000821:virology*; D006512:Hepatitis B Core Antigens / Q000235:genetics*; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology*; D008969:Molecular Sequence Data; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D011401:Promoter Regions, Genetic
chemical_list: D000998:Antiviral Agents; D006512:Hepatitis B Core Antigens; D019259:Lamivudine